In a report released today, Oren Livnat from H.C. Wainwright reiterated a Buy rating on Pacira Pharmaceuticals (NASDAQ: PCRX), with a price target of $48. The company’s shares opened today at $35.60.
Livnat said:
“Valuation and risks. Our $48 12-month target is based on an average of our $55/share DCF (10% WACC discount rate; 1% terminal growth beyond 2024) and a $41/share P/E multiple derived valuation (30x fully-taxed 2020 EPS, or 1x PEG, discounted back).”
According to TipRanks.com, Livnat is a 1-star analyst with an average return of -3.7% and a 47.6% success rate. Livnat covers the Healthcare sector, focusing on stocks such as Zynerba Pharmaceuticals, Jazz Pharmaceuticals, and Agile Therapeutics.
Currently, the analyst consensus on Pacira Pharmaceuticals is a Hold with an average price target of $46.
See today’s analyst top recommended stocks >>
Based on Pacira Pharmaceuticals’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $10.68 million. In comparison, last year the company had a GAAP net loss of $19.74 million.
Based on the recent corporate insider activity of 33 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Pacira Pharmaceuticals, Inc. is a holding company, which engages in the development, commercialization, and manufacture of pharmaceutical products for use in postsurgical outcomes for acute care practitioners and their patients.
